It has also been reported that rising concentrations of soluble CA125 were detected in breast cancer, mesothelioma, gastric cancer, colorectal adenocarcinoma, etc. In colorectal adenocarcinomas, CA125 has been tested as a potential applicability future serological marker in comparison with other tumor markers such as carcinoembryonic antigen (CEA). This evidence concerns the gene MUC16 and breast carcinoma.